| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| 100mg | |||
| Other Sizes |
| Targets |
COX-1 (IC50 = 0.3 mM); COX-2 (IC50 = 0.57 mM)
- Hamaudol targets cyclooxygenase-2 (COX-2) with an IC50 value of 0.57 mM, and cyclooxygenase-1 (COX-1) with an IC50 value of 0.30 mM (as measured in an in vitro radiochemical assay using purified enzymes). [2] |
|---|---|
| ln Vitro |
- Hamaudol demonstrated inhibitory activity on COX-1 with an IC50 value of 0.30 mM. In the same assay, it showed inhibitory activity on COX-2 with an IC50 value of 0.57 mM. The compound was tested at multiple concentrations (1.0, 0.2, 0.04, 0.008 mM) to determine the IC50 values via linear regression. [2]
|
| ln Vivo |
Compound 7, or hamaudol, had no discernible dose dependence in rats, but it did enhance strong analgesic effects at doses of 1, 5, and 10 mg/kg [1].
- In the acetic acid-induced writhing test in mice, Hamaudol (referred to as hamadoul) showed significant writhing inhibition at an oral dose of 1 mg/kg (p < 0.01). The inhibition percentage was determined relative to a control group (saline), with the number of control squirms taken as 100%. [1] |
| Enzyme Assay |
- The cyclooxygenase (COX) inhibition assay was performed using purified COX-1 and COX-2 enzymes. Briefly, 10 µg of the enzyme (COX-1 or COX-2) was activated on ice for 4 minutes with 170 µg of a cofactor solution containing hematin, l-ephedrine, and reduced glutathione in Tris-HCl buffer (pH 8.0). Then, 10 µL of the test solution containing Hamaudol (dissolved in DMSO) or vehicle control (DMSO) was added to the reaction tube and preincubated on ice for 10 minutes. The reaction was initiated by adding 10 µL of [1-14C] arachidonic acid and the mixture was incubated for 20 minutes at 37°C. The reaction was stopped by adding 10 µL of 2 M HCl. The prostaglandins produced and the unmetabolized arachidonic acid were extracted with ethyl ether and separated by TLC using a developing system of CHCl3-MeOH-acetic acid (18:1:1). The amount of 14C-labeled PGE2 produced was measured using electronic autoradiography. The inhibitory effect of Hamaudol was expressed as the percentage of PGE2 produced compared to the DMSO control. IC50 values (0.30 mM for COX-1 and 0.57 mM for COX-2) were obtained by linear regression analysis of results from three different concentrations of the test sample. [2]
|
| Animal Protocol |
- Acetic acid-induced writhing test for analgesia: Male ddy strain mice (weighing 24-36 g, 4 weeks old) were used. Hamaudol (referred to as hamadoul) was dissolved or suspended in water with 5% Tween 80. The compound was administered orally at a dose of 1 mg/kg (0.1 mL/10 g mouse). A positive control (aminopyrine 50 mg/kg) was used. After sample administration, 0.7% acetic acid was injected intraperitoneally. Following a 5-minute waiting period, the number of squirms (writhing responses) was counted for each mouse over the next 15 minutes. Analgesic activity was expressed as the percentage of writhing inhibition compared to the control group (saline). The significance of the effect was calculated (p < 0.01). [1]
|
| References | |
| Additional Infomation |
Hamodo belongs to the chromene class of compounds. It has been reported that Hamodo exists in Angelica juncea, Pseudomonas japonica, and other organisms with relevant data.
- Hamaudol is a chromone compound. In the study on Saposhnikovia divaricata, it was identified as one of the most potent analgesic components, along with divaricatol and ledebourilol, showing significant writhing inhibition at an oral dose of 1 mg/kg in mice. The analgesic activity of the related chromone sec-O-glucosylhamadoul (compound 1) was not reversed by naloxone, suggesting the analgesic pathway for this class of compounds may be related to an opioid receptor, although this specific experiment was not performed directly on Hamaudol. [1] - In Peucedanum japonicum, Hamaudol (compound 7) was isolated from the CHCl3 fraction and was considered to be the main inhibitory compound against COX-2, suggesting it might be a lead compound for the development of COX-2 inhibitors. Its inhibitory activity against COX-2 (IC50 = 0.57 mM) was lower than that of the positive control indomethacin (IC50 = 0.08 mM). [2] |
| Molecular Formula |
C15H16O5
|
|---|---|
| Molecular Weight |
276.2845
|
| Exact Mass |
276.1
|
| CAS # |
735-46-6
|
| PubChem CID |
164722
|
| Appearance |
White to off-white solid
|
| Boiling Point |
464.7±45.0 °C at 760 mmHg
|
| Melting Point |
197.0-197.5 °C
|
| Source |
Originated from plants: Compositae Ophryosporus axilliflorus Hieron.
Originated from plants: Umbelliferae |
| LogP |
1.881
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
20
|
| Complexity |
455
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O1C2C([H])=C3C(C(C([H])=C(C([H])([H])[H])O3)=O)=C(C=2C([H])([H])[C@@]([H])(C1(C([H])([H])[H])C([H])([H])[H])O[H])O[H]
|
| InChi Key |
VOTLUFSYIRHICX-LBPRGKRZSA-N
|
| InChi Code |
InChI=1S/C15H16O5/c1-7-4-9(16)13-11(19-7)6-10-8(14(13)18)5-12(17)15(2,3)20-10/h4,6,12,17-18H,5H2,1-3H3/t12-/m0/s1
|
| Chemical Name |
(3S)-3,5-dihydroxy-2,2,8-trimethyl-3,4-dihydropyrano[3,2-g]chromen-6-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~6.3 mg/mL (~22.6 mM; with ultrasonication and warming by heating to 60°C)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.62 mg/mL (2.24 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (6.2 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6195 mL | 18.0976 mL | 36.1952 mL | |
| 5 mM | 0.7239 mL | 3.6195 mL | 7.2390 mL | |
| 10 mM | 0.3620 mL | 1.8098 mL | 3.6195 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
